Risk–Benefit Trade-offs of GLP-1RAs and SGLT-2is in Type 2 Diabetes Mellitus (T2D): Systematic Review, Meta-Analysis, and Net Benefit Modeling
Open Access
- 7 November 2025
- journal article
- review article
- Published by Springer Nature in Diabetes Therapy
- Vol. 17 (1) , 55-72
Abstract
Introduction While glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT-2is) are established for cardiorenal benefits in type 2 diabetes mellitus (T2DM), prior meta-analyses have not fully integrated cross-class comparisons or net benefit analyses with updated cardiovascular outcome trials (CVOTs). Methods We conducted a systematic review and meta-analysis of 17 CVOTs (N = 132,038; GLP-1RA: N = 73,263; SGLT-2i: N = 58,775) using PubMed and Cochrane CENTRAL. We uniquely synthesized major adverse cardiovascular events (MACE), hospitalization for heart failure (hHF), renal composites, and safety outcomes (e.g., retinopathy, genitourinary infections) with random-effects models for hazard ratios (HRs) and relative risks (RRs). Innovative graphical syntheses (tornado/scatter plots, risk curves) and net benefit calculations (absolute risk reductions [ARRs] minus absolute excess risks [AERs]) were employed. Risk of bias (RoB 2) and GRADE certainty were assessed. Results Both classes reduced MACE (HR 0.87, 95% CI 0.84–0.90; p = 0.73 for class difference). SGLT-2is were superior for hHF (HR 0.69 vs. 0.88, p < 0.0001) and renal outcomes (HR 0.68 vs. 0.79, p = 0.026). GLP-1RAs increased retinopathy (RR 1.18, AER + 6.5/1000); SGLT-2is increased genitourinary infections (RR 3.34, AER + 19.9/1000) and DKA (RR 2.67, AER + 1.2/1000). Amputation signals attenuated post-sensitivity analysis. Net benefits favored GLP-1RAs for MACE (+ 2.5/1000). For SGLT-2is, base-case estimates using genital-mycotic infections as the sentinel harm were marginal (hHF: − 4.9/1000; renal: − 1.9/1000), whereas sensitivity scenarios with alternative harms (e.g., volume depletion, amputation, DKA) yielded positive net benefits. GRADE certainty was high for efficacy, moderate for harms. Conclusions Our innovative integration of updated CVOTs, cross-class comparisons, and graphical risk–benefit tools refines therapeutic decision-making, highlighting tailored T2DM management based on patient-specific cardiorenal risks. Trial Registration PROSPERO (CRD420251146788).Keywords
This publication has 46 references indexed in Scilit:
- SGLT2 inhibitors across various patient populations in the era of precision medicine: the multidisciplinary team approachnpj Metabolic Health and Disease, 2025
- Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbiditiesPeptides, 2025
- Cardiovascular and renal effects of the combination therapy of a GLP-1 receptor agonist and an SGLT2 inhibitor in observational real-life studiesDiabetes & Metabolism, 2024
- Glucagon-like peptide-1 receptor: mechanisms and advances in therapySignal Transduction and Targeted Therapy, 2024
- Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trialsAmerican Journal of Preventive Cardiology, 2024
- Diabetes mellitus, the fastest growing global public health concern: Early detection should be focusedHealth Science Reports, 2024
- Chapter 2: Clinical and Mechanistic Potential of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors in Heart Failure with Preserved Ejection FractionThe American Journal of Medicine, 2023
- Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective StudyDiabetes Therapy, 2022
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialThe Lancet, 2019
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trialThe Lancet, 2018